It has been reported that MSCs administered in patients with moderate-to-severe atopic dermatitis (AD) could reduce allergic symptoms and inflammatory parameters via reduction of serum immunoglobulin E (IgE) levels and eosinophil count without the occurrence of serious AE [24]. This evidence concerns the gene IGHE and Alzheimer disease.